Alexander Pasternak
Research Subjects
Research Interests
Alexander Pasternak has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Lihu Yang
Merck Research Laboratories , Rahway, New Jersey 07065, United States
4 shared publicationsSander G. Mills
Merck Research Laboratories , Rahway, New Jersey 07065, United States
4 shared publicationsPasquale P. Vicario
Merck Research Laboratories, Rahway, New Jersey 07065
3 shared publicationsAndrew D. Howard
Merck Research Laboratories , Rahway, New Jersey 07065, United States
2 shared publicationsJulia M. Ayala
Merck Research Laboratories, Rahway, New Jersey 07065
2 shared publicationsJulie A. DeMartino
Merck Research Laboratories, Rahway, New Jersey 07065
2 shared publications
Latest Publications
- Open Access
- 19 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (5) , 1539-1546
Live cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7–Lin28 RNA–protein interaction
Dysregulation of the networking of RNA-binding proteins (RBPs) and RNAs drives many human diseases, including cancers, and the targeting of RNA–protein interactions (RPIs) has emerged as an exciting area of RNA-targeted drug discovery.
- 19 March 2024
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (5) , 1539-1546
Open AccessLive cell screening to identify RNA-binding small molecule inhibitors of the pre-let-7–Lin28 RNA–protein interaction
Dysregulation of the networking of RNA-binding proteins (RBPs) and RNAs drives many human diseases, including cancers, and the targeting of RNA–protein interactions (RPIs) has emerged as an exciting area of RNA-targeted drug discovery.
- Open Access
- 3 December 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0243145
Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function
Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-specific Ste20-related serine/threonine kinase, is a negative regulator of signal transduction in immune cells, including T cells, B cells, and dendritic cells (DCs). In mice, HPK1 deficiency subverts inhibition of the anti-tumor immune response and is associated with functional augmentation of anti-tumor T cells. We have used a potent, small molecule HPK1 inhibitor, Compound 1, to investigate the effects of pharmacological intervention of HPK1 kinase activity in immune cells. Compound 1 enhanced Th1 cytokine production in T cells and fully reverted immune suppression imposed by the prostaglandin E2(PGE2) and adenosine pathways in human T cells. Moreover, the combination of Compound 1 with pembrolizumab, a humanized monoclonal antibody against the programmed cell death protein 1 (PD-1), demonstrated a synergistic effect, resulting in enhanced interferon (IFN)-γ production. Collectively, our results suggest that blocking HPK1 kinase activity with small molecule inhibitors alone or in combination with checkpoint blockade may be an attractive approach for the immunotherapy of cancer.
- 3 December 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0243145
Open AccessPharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function
Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-specific Ste20-related serine/threonine kinase, is a negative regulator of signal transduction in immune cells, including T cells, B cells, and dendritic cells (DCs). In mice, HPK1 deficiency subverts inhibition of the anti-tumor immune response and is associated with functional augmentation of anti-tumor T cells. We have used a potent, small molecule HPK1 inhibitor, Compound 1, to investigate the effects of pharmacological intervention of HPK1 kinase activity in immune cells. Compound 1 enhanced Th1 cytokine production in T cells and fully reverted immune suppression imposed by the prostaglandin E2(PGE2) and adenosine pathways in human T cells. Moreover, the combination of Compound 1 with pembrolizumab, a humanized monoclonal antibody against the programmed cell death protein 1 (PD-1), demonstrated a synergistic effect, resulting in enhanced interferon (IFN)-γ production. Collectively, our results suggest that blocking HPK1 kinase activity with small molecule inhibitors alone or in combination with checkpoint blockade may be an attractive approach for the immunotherapy of cancer.
- 27 October 2017
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 9 (16) , 1963-1977
The Therapeutic Potential of Targeting the K Ir 1.1 (Renal Outer Medullary K + ) Channel
Kir1.1 (renal outer medullary K+) channels are potassium channels expressed almost exclusively in the kidney and play a role in the body's electrolyte and water balance. Potassium efflux through Kir1.1 compliments the role of transporters and sodium channels that are the targets of known diuretics. Consequently, loss-of-function mutations in men and rodents are associated with salt wasting and low blood pressure. On this basis, Kir1.1 inhibitors may have value in the treatment of hypertension and heart failure. Efforts to develop small molecule Kir1.1 inhibitors produced MK-7145, which entered into clinical trials. The present manuscript describes the structure–activity relationships associated with this scaffold alongside other preclinical Kir1.1 blockers.
- 27 October 2017
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 9 (16) , 1963-1977
The Therapeutic Potential of Targeting the K Ir 1.1 (Renal Outer Medullary K + ) Channel
Kir1.1 (renal outer medullary K+) channels are potassium channels expressed almost exclusively in the kidney and play a role in the body's electrolyte and water balance. Potassium efflux through Kir1.1 compliments the role of transporters and sodium channels that are the targets of known diuretics. Consequently, loss-of-function mutations in men and rodents are associated with salt wasting and low blood pressure. On this basis, Kir1.1 inhibitors may have value in the treatment of hypertension and heart failure. Efforts to develop small molecule Kir1.1 inhibitors produced MK-7145, which entered into clinical trials. The present manuscript describes the structure–activity relationships associated with this scaffold alongside other preclinical Kir1.1 blockers.
- 1 March 2012
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (4) , 289-293
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist
This letter provides the first pharmacological proof of principle that the sst3 receptor mediates glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. To enable these studies, we identified the selective sst3 antagonist (1R,3R)-3-(5-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-β-carboline (5a), with improved ion channel selectivity and mouse pharmacokinetic properties as compared to previously described tetrahydro-β-carboline imidazole sst3 antagonists. We demonstrated that compound 5a enhances GSIS in pancreatic β-cells and blocks glucose excursion induced by dextrose challenge in ipGTT and OGTT models in mice. Finally, we provided strong evidence that these effects are mechanism-based in an ipGTT study, showing reduction of glucose excursion in wild-type but not sst3 knockout mice. Thus, we have shown that antagonism of sst3 represents a new mechanism with potential in treating type 2 diabetes mellitus.
- 1 March 2012
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 3 (4) , 289-293
Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist
This letter provides the first pharmacological proof of principle that the sst3 receptor mediates glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. To enable these studies, we identified the selective sst3 antagonist (1R,3R)-3-(5-phenyl-1H-imidazol-2-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-β-carboline (5a), with improved ion channel selectivity and mouse pharmacokinetic properties as compared to previously described tetrahydro-β-carboline imidazole sst3 antagonists. We demonstrated that compound 5a enhances GSIS in pancreatic β-cells and blocks glucose excursion induced by dextrose challenge in ipGTT and OGTT models in mice. Finally, we provided strong evidence that these effects are mechanism-based in an ipGTT study, showing reduction of glucose excursion in wild-type but not sst3 knockout mice. Thus, we have shown that antagonism of sst3 represents a new mechanism with potential in treating type 2 diabetes mellitus.
- 28 December 2009
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (1) , 14-18
Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
- 28 December 2009
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 1 (1) , 14-18
Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
- 1 November 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (21) , 6237-6240
Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists
- 1 November 2009
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (21) , 6237-6240
Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists
- 1 February 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (3) , 994-998
Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists
- 1 February 2008
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (3) , 994-998
Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists
- 11 July 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (16) , 4801-4804
Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists
Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an ongoing program targeting CCR2 antagonists. Optimization of 11 leading to antagonists 26 and 37 is described. Antagonist 26 was shown to have good oral bioavailability in rats. Antagonist 37 had a CCR2 IC50 of 59 nM and excellent potency in a functional assay measuring inhibition of MCP-1 induced monocyte chemotaxis (IC50 of 41 nM).
- 11 July 2006
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (16) , 4801-4804
Novel, Orally Bioavailable γ-Aminoamide CC Chemokine Receptor 2 (CCR2) Antagonists
Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4-(4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an ongoing program targeting CCR2 antagonists. Optimization of 11 leading to antagonists 26 and 37 is described. Antagonist 26 was shown to have good oral bioavailability in rats. Antagonist 37 had a CCR2 IC50 of 59 nM and excellent potency in a functional assay measuring inhibition of MCP-1 induced monocyte chemotaxis (IC50 of 41 nM).